

<b>General information about company</b>	
Scrip code	542650
NSE Symbol	METROPOLIS
MSEI Symbol	NOTLISTED
ISIN*	INE112L01020
Name of company	METROPOLIS HEALTHCARE LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2019
Date of end of financial year	31-03-2020
Date of board meeting when results were approved	29-05-2020
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	25-05-2020
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Audited
Segment Reporting	Single segment
Description of single segment	Pathology
Start date and time of board meeting	29-05-2020 14:20
End date and time of board meeting	29-05-2020 17:05
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-01-2020	01-04-2019
B	Date of end of reporting period	31-03-2020	31-03-2020
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	20697.45	85640.54
	Other income	307.12	856.66
	<b>Total income</b>	<b>21004.57</b>	<b>86497.2</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	5094.3	20413.5
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	4492.05	19015.62
(e)	Finance costs	227.74	834.47
(f)	Depreciation, depletion and amortisation expense	1114.42	3926.72
<b>(f)</b>	<b>Other Expenses</b>		
1	Other Expenses	5711.49	22239.95
2	Laboratory testing Charges	259.61	688.99
10			
	<b>Total other expenses</b>	<b>5971.1</b>	<b>22928.94</b>
	<b>Total expenses</b>	<b>16899.61</b>	<b>67119.25</b>

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-01-2020	01-04-2019
B	Date of end of reporting period	31-03-2020	31-03-2020
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	4104.96	19377.95
4	Exceptional items	-1766.18	-2452.66
<b>5</b>	<b>Total profit before tax</b>	2338.78	16925.29
<b>7</b>	<b>Tax expense</b>		
8	Current tax	1665.58	5037.43
9	Deferred tax	-876.14	-919.33
<b>10</b>	<b>Total tax expenses</b>	789.44	4118.1
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	1549.34	12807.19
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	-51.98
<b>21</b>	<b>Total profit (loss) for period</b>	1549.34	12755.21

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-01-2020	01-04-2019
B	Date of end of reporting period	31-03-2020	31-03-2020
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
1	Items that will not be reclassified subsequent ly to profit and loss (net of tax)	-127.2	-300.15
	<b>Total Amount of items that will not be reclassified to profit and loss</b>	-127.2	-300.15
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	0	0
<b>3 Amount of items that will be reclassified to profit and loss</b>			
1	Items that will be subsequent ly reclassified to profit and loss (net of tax)	0	0
	<b>Total Amount of items that will be reclassified to profit and loss</b>	0	0
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0	0
5	<b>Total Other comprehensive income</b>	-127.2	-300.15

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-01-2020	01-04-2019
B	Date of end of reporting period	31-03-2020	31-03-2020
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	1422.14	12455.06
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent	1549.29	12732.56
	Total profit or loss, attributable to non-controlling interests	0.05	22.66
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	1421.74	12432.37
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0.4	22.69
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	1012.61	1012.61
	Face value of equity share capital	2	2
<b>27</b>	<b>Details of debt securities</b>		
<b>28</b>	Reserves excluding revaluation reserve		52515.37
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	3.09	25.36
	Diluted earnings (loss) per share from continuing operations	3.07	25.25
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	3.09	25.36
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	3.07	25.25
<b>30</b>	Debt equity ratio		
<b>31</b>	Debt service coverage ratio		
<b>32</b>	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>		

<b>Statement of Asset and Liabilities</b>	
Particulars	Current year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2019
Date of end of reporting period	31-03-2020
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Consolidated
<b>Assets</b>	
<b>1 Non-current assets</b>	
Property, plant and equipment	12119.62
Capital work-in-progress	0
Investment property	0
Goodwill	9034.79
Other intangible assets	8482.75
Intangible assets under development	298.73
Biological assets other than bearer plants	0
Investments accounted for using equity method	0
<b>Non-current financial assets</b>	
Non-current investments	175.28
Trade receivables, non-current	
Loans, non-current	546.7
Other non-current financial assets	1239.34
<b>Total non-current financial assets</b>	<b>1961.32</b>
Deferred tax assets (net)	1390.11
Other non-current assets	2229.91
<b>Total non-current assets</b>	<b>35517.23</b>
<b>2 Current assets</b>	
Inventories	2440.07
<b>Current financial asset</b>	
Current investments	1256.61
Trade receivables, current	12824.78
Cash and cash equivalents	10717.42
Bank balance other than cash and cash equivalents	10329.7
Loans, current	1118.07
Other current financial assets	217.1
<b>Total current financial assets</b>	<b>36463.68</b>
Current tax assets (net)	
Other current assets	802.19
<b>Total current assets</b>	<b>39705.94</b>

<b>Statement of Asset and Liabilities</b>		
	Particulars	Current year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2019
	Date of end of reporting period	31-03-2020
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Consolidated
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	<b>Total assets</b>	<b>75223.17</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
<b>Equity attributable to owners of parent</b>		
	Equity share capital	1012.61
	Other equity	51337
	<b>Total equity attributable to owners of parent</b>	<b>52349.61</b>
	Non controlling interest	165.76
	<b>Total equity</b>	<b>52515.37</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
	Borrowings, non-current	0
	Trade payables, non-current	
	Other non-current financial liabilities	5045.62
	<b>Total non-current financial liabilities</b>	<b>5045.62</b>
	Provisions, non-current	541.4
	Deferred tax liabilities (net)	172.82
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	<b>Total non-current liabilities</b>	<b>5759.84</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
	Borrowings, current	0
	Trade payables, current	8503.4
	Other current financial liabilities	5530.33
	<b>Total current financial liabilities</b>	<b>14033.73</b>
	Other current liabilities	1881.15
	Provisions, current	659.91
	Current tax liabilities (Net)	373.17
	Deferred government grants, Current	0
	<b>Total current liabilities</b>	<b>16947.96</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	<b>Total liabilities</b>	<b>22707.8</b>
	<b>Total equity and liabilities</b>	<b>75223.17</b>
<b>Disclosure of notes on assets and liabilities</b>		Textual Information(1)

**Text Block**

Textual Information(1)

These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) prescribed under Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.

The above audited results were reviewed by the Audit Committee at their meeting held on 29 05 2020 and thereafter approved by the Board of Directors at their meeting held on 29 05 2020. The statutory auditors have expressed unqualified audit opinion. The Group has adopted Ind AS 116, effective annual reporting period beginning 01.04.2019 and applied the standard to its leases, retrospectively, with the cumulative effect of initially applying the Standard, recognised on the date of initial application (01 04 2019). Accordingly, the Group has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on 01 04 2019. The Group has adopted Ind AS 116 using the cumulative effect method for transitioning.

Exceptional items in the consolidated financial results for the year ended 31 03 2020 includes: -

- provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 Lakhs and; provision for Rs.350 Lakhs on account of certain old unreconciled balances. There has been a prolonged dispute in relation to trade receivables from a party towards lab management services rendered by the Company and the matter has been under arbitration. In view of the delay, the Company, on a prudent basis, has made provision aggregating Rs 1,766 Lakhs against the above mentioned disputed trade receivables and this has been disclosed as an exceptional item.

Disclosure of segment –wise information is not applicable, as pathology services is the Group’s only business segment. The Company under Metropolis Employee Stock Option Plan 2015 “(MESOP 2015), 451,886 Equity shares allotted pursuant to exercise of option in February 2020.

The Company has through its wholly owned subsidiary Desai Metropolis Health Services Private Limited, has acquired four Laboratories from: (i) Doctor's Clinical Laboratory (ii) Iyer Pathology Laboratory, (iii) Nagar Pathology Laboratory and (iv) Yash Clinical Laboratory, for providing diagnostic and pathological testing services in Surat, Gujarat as on 30 09 2019 for purchase consideration of Rs. 1,800 lakhs payable in 3 tranches starting from 30 09 2019. The Company is in process of acquiring 51% shareholding of Shradha Diagnostic Centre (I) Private Limited for providing diagnostic and pathological testing services in Ahmedabad, Gujarat as approved in Board Meeting held on 15 01 2020 to strengthen the presence of the Company in the state of Gujarat for purchase consideration of Rs 936.30 lakhs. The same is expected to be closed on 30 06 2020. The figures for the three months ended 31 03 2020 are arrived at as difference between audited figures in respect of full financial year and the unaudited published figures upto nine months ended December 31 of the relevant financial year. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit. The consolidated financial results for the quarter ended 31 03 2019 are not subject to audit/ limited review by the statutory auditors and are prepared by the Company’s management. The Board of Directors of the Company have approved the interim dividend of Rs 8 per equity share (Face value of Rs 2 each) at the meeting held on 06 02 2020. The Company and its Indian subsidiary companies have elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. The results of the Company are available for investors at [www.metropolisindia.com](http://www.metropolisindia.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).



<b>Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results</b>		
<b>Particulars</b>	<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
Date of start of reporting period	01-01-2020	01-04-2019
Date of end of reporting period	31-03-2020	31-03-2020
Whether accounts are audited or unaudited		
Nature of report standalone or consolidated	Consolidated	Consolidated
<b>1 Segment Revenue (Income)</b>		
<b>(net sale/income from each segment should be disclosed)</b>		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
<b>2 Segment Result</b>		
<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
<b>3 (Segment Asset - Segment Liabilities)</b>		
<b>Segment Asset</b>		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
<b>4 Segment Liabilities</b>		
<b>Segment Liabilities</b>		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
<b>Disclosure of notes on segments</b>		